|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 47/61 | (2017.01) |
| A61P 35/00 | (2006.01) | ||
| C08B 37/08 | (2006.01) | ||
| C08L 5/08 | (2006.01) |
| (11) | Number of the document | 4132587 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21717556.1 |
| Date of filing the European patent application | 2021-04-07 | |
| (97) | Date of publication of the European application | 2023-02-15 |
| (45) | Date of publication and mention of the grant of the patent | 2024-05-01 |
| (46) | Date of publication of the claims translation | 2024-07-25 |
| (86) | Number | PCT/IB2021/052870 |
| Date | 2021-04-07 |
| (87) | Number | WO 2021/205350 |
| Date | 2021-10-14 |
| (30) | Number | Date | Country code |
| 202000007747 | 2020-04-10 | IT |
| (72) |
PIZZOCARO, Carlo , IT
ROSATO, Antonio , IT
|
| (73) |
Fidia Farmaceutici S.p.A. ,
Via Ponte della Fabbrica 3/A, 35031 Abano Terme (PD),
IT
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | HA-paklitakselio konjugatas, skirtas mezoteliomos gydymui |
| HA-PACLITAXEL CONJUGATE FOR TREATMENT OF MESOTHELIOMA |
| Payment date | Validity (years) | Amount | |
| 2025-03-18 | 5 | 115.00 EUR |
| 2026-04-07 |